This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Frederic M. Quitkin, MD; Michael R. Liebowitz, MD; Jonathan W. Stewart, MD; Patrick J. McGrath, MD; Wilma Harrison, MD; Judith G. Rabkin, PhD; Jeffrey Markowitz, MPH; Sharon O. Davies, RN

Arch Gen Psychiatry. 1984;41(8):777-781.

Abstract
• We investigated the antidepressant efficacy of l-deprenyl (selegiline), a selective monoamine oxidase B inhibitor (MAOI), in a six-week open trial of 17 patients with atypical depression. Such patients have previously been shown to benefit from nonselective MAOIs such as phenelzine sulfate. Ten patients (59%) responded to l-deprenyl, but nine required dosages above the 10 to 20 mg/day used in previous investigations. l-Deprenyl was superior to six weeks of placebo administered to diagnostically similar patients in a separate double-blind study. In contrast with previous findings with phenelzine, responders to l-deprenyl differed from nonresponders by having lower baseline anxiety ratings. Even at high dosages, there appeared to be fewer side effects with l-deprenyl than with nonselective MAOIs.

Author Affiliations
From the New York State Psychiatric Institute, New York; and the Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York (Drs Quitkin, Liebowitz, Stewart, McGrath, Harrison, and Rabkin and Mr Markowitz).

Footnotes
Accepted for publication Feb 28, 1984.

Reprint requests to New York State Psychiatric Institute, 722 W 168th St, New York, NY 10032 (Dr Quitkin).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Chronological Milestones to Guide Drug Change: When Should Clinicians Switch Antidepressants?
Quitkin et al.
Arch Gen Psychiatry 1996;53:785-792.
ABSTRACT  

High-Dose Selegiline in Treatment-Resistant Older Depressive Patients
Sunderland et al.
Arch Gen Psychiatry 1994;51:607-615.
ABSTRACT  

A Pilot Study of Low-Dose L-Deprenyl in Alzheimer's Disease
Schneider et al.
J Geriatr Psychiatry Neurol 1991;4:143-148.
ABSTRACT  

A Controlled Study of the Antidepressant Efficacy and Side Effects of ( -- )-Deprenyl: A Selective Monoamine Oxidase Inhibitor
Mann et al.
Arch Gen Psychiatry 1989;46:45-50.
ABSTRACT  

Predictors of Drug Response in Depression
Joyce and Paykel
Arch Gen Psychiatry 1989;46:89-99.
ABSTRACT  

Antidepressant Specificity in Atypical Depression
Liebowitz et al.
Arch Gen Psychiatry 1988;45:129-137.
ABSTRACT  

L-Deprenyl in Alzheimer's Disease: Preliminary Evidence for Behavioral Change With Monoamine Oxidase B Inhibition
Tariot et al.
Arch Gen Psychiatry 1987;44:427-433.
ABSTRACT